Clinical Focus in SCLC: Emerging Insights on B7-H3–Targeted ADCs and Their Transformative Potential in Clinical Practice

Enhance your understanding of the rationale for integrating antibody–drug conjugates (ADCs) targeting B7-H3 into the treatment of small-cell lung cancer (SCLC) to better educate patients, caregivers, and colleagues and gain insight into clinical trials on these agents through a podcast, a text module with accompanying downloadable slides, and an expert ClinicalThought commentary.

Share

Program Content

No activities added yet

No activities added yet

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc.